Bravecto® chewable tablets for dogs
Bravecto Chewable Tablets are indicated for the treatment of important ectoparasites of dogs including fleas, ticks and for Sarcoptes and Demodex mites. Based on the isoxazoline active ingredient, fluralaner, a duration of efficacy for both fleas and ticks has been demonstrated for up to 12 weeks* following dosage with a single chew.
Information on ordering Bravecto is available after login.
Presentation
Bravecto is a pork-flavoured chewable tablet presented in child resistant, foil wrapped, packs of either one or two tablets.
Active ingredients
Bravecto is an ectoparasiticide treatment for dogs that contains the active ingredient fluralaner.
Target species
Dogs
Indications for use
For the treatment of tick and flea infestations in dogs.
This veterinary medicinal product is a systemic insecticide and acaricide that provides:
- immediate and persistent flea (Ctenocephalides felis) killing activity for 12 weeks,
- immediate and persistent tick killing activity for 12 weeks for Ixodes ricinus, Dermacentor reticulatus and D. variabilis,
- immediate and persistent tick killing activity for 8 weeks for Rhipicephalus sanguineus.
- persistent tick killing activity from 7 days to 12 weeks after treatment for Ixodes hexagonus.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
For the treatment of demodicosis caused by Demodex canis.
For the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation.
For reduction of the risk of infection with Babesia canis canis via transmission by Dermacentor reticulatus for up to 12 weeks. The effect is indirect due to the veterinary medicinal product’s activity against the vector.
For reduction of the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis for up to 12 weeks. The effect is indirect due to the veterinary medicinal product’s activity against the vector.
Packaging
Bravecto is presented in child resistant packaging. It comes in a range of sizes to suit toy, small, medium and large dogs.
Legal Category
POM-V
Frequently Asked Questions
-
Bravecto® dosing and a growing puppy
A growing dog should be dosed with a tablet appropriate to the body weight at the time of treatment.
Field studies conducted in support of Bravecto’s marketing authorisation included growing dogs and there was no evidence for a lack of efficacy1,2. Bravecto showed continuous flea efficacy of >99% throughout the 12-week interval in these dogs. The minimum retreatment interval for dogs is 8 weeks3.
1. Meadows et al. Parasites & Vectors 2014, 7:375
2. Rohdich et al. Parasites & Vectors 2014, 7:83
3. Bravecto chewable tablets summary of product characteristics -
Does Bravecto® have any breed specific contraindications?
There are no breed contraindications for this product. Any contraindications are listed in the product datasheet under summary of product characteristics.
-
Swapping to Bravecto® from another flea treatment
There are no known incompatibilities with other classes of ectoparasiticides or parasiticide. It would be a reasonable precaution to observe a normal retreatment interval after the use of another product in the isoxazoline class and in the case of other products to not apply two products simultaneously so it was clear which product use was responsible in the unlikely occurrence of an adverse event.
-
Bravecto® and Environmental impact
MSD Animal Health conducts environmental risk assessments on its products from the development phase through product launch to understand and manage product impacts from manufacturing and patient use. Our environmental risk assessments are conducted in accordance with applicable stringent global regulations, including the regulatory review processes of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Product environmental safety profiles are reassessed during periodic renewals of product filings and risk mitigation actions are implemented when needed.
The potential transfer of active ingredients used in our spot-on and chew products from the dog into surface water has been assessed in the European environmental risk assessments. Based on their intrinsic properties we are confident in the absence of transfer into surface water for the active ingredients in the registered products in our companion animal line. However, please be aware of the statement on the Summary of Product Characteristics that dogs treated with Bravecto Spot-On should not be allowed to be immersed in water or swim in water courses within 3 days after treatment. There is no specifically identified risk to fish or aquatic species from this activity.
Following oral treatment of dogs fluralaner will mainly be excreted via the faeces, thus exposure of bees to fluralaner is considered very unlikely. Overall, there were no environmental concerns identified in the regulatory submissions or reviews. The environmental exposure through the oral treatment of dogs is considered too low to impact the environment.
-
What is the last day that Bravecto® can be given?
The expiry date of the product is stated on the packaging and refers to the last day of that month. Do not use the product after the expiry date.
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: January 2026
References
* Bravecto Chew provides 12-week immediate and persistent killing activity against fleas (Ctenocephalides felis), 12-week immediate and persistent killing activity against the ticks Ixodes ricinus, Dermacentor reticulatus and D. variabilis and 8-week immediate and persistent killing activity against Rhipicephalus sanguineus.